RxDoctor Payments Data

Elizabeth Sykes, NP

Family · Memphis, TNNPI 1730615709

Payments from drug & device makers

$4,876in general payments, 2019–2025

Across 292 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$671
  • Pfizer$595
  • Philips North America LLC$535
  • Actelion Pharmaceuticals US, Inc.$493
  • Boehringer Ingelheim$431
  • Amarin Pharma, Inc.$344
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,876100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,876 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$115,706
Medicare patients
504
Services billed
2,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban25$26,092
EntrestoSacubitril/Valsartan17$13,204
EliquisApixaban17$10,170
JardianceEmpagliflozin13$8,768
SotalolSotalol Hcl207$5,509
Isosorbide Mononitrate ErIsosorbide Mononitrate112$1,888
Midodrine Hcl29$1,832
Doxazosin Mesylate62$1,488
Amlodipine Besylate138$1,260
Losartan Potassium65$1,060
Digoxin55$962
Potassium Chloride35$843
Verapamil ErVerapamil Hcl20$765
Metoprolol Succinate46$677
Pentoxifylline17$632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$343$26,09225 claims
NovartisEntresto$671$13,20417 claims
PfizerEliquis$595$10,17017 claims
Boehringer IngelheimJardiance$431$8,76813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.

Other family in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →